Table 1. Socio-demographic and medical data of the study population.
| Patients | M0 (141) | M12 (76) |
| Sex (Male/Female) | 42/99 | 21/55 |
| Median CD4 (IQR) | 125 (51–208) | Not applicable |
| Exposure to ARV for PMTCT | 2 | Not applicable |
| Still on ART | Not applicable | 76 |
| 3TC+AZT+NVP/EFV | 129 | 44 |
| 3TC+d4T+NVP/EFV | 9 | 31 |
| Other HAART | 3 (2 on protease inhibitors) | 1 |
| Treatment interruption | Not applicable | 0 |
| Deceased | Not applicable | 13 |
| Lost-to-follow-up (LTFU) | Not applicable | 47 |
| Transferred out | Not applicable | 5 |
| >90% Adherence to ART in the past 30 days | Not applicable | 93,4% |
| Treatment switch within first-line ART | Not applicable | 29 (20 due to drug shortages) |
| Change to second line ART | Not applicable | 0 |
Legend table 1: ART: Antiretroviral therapy; HAART: Highly Active Antiretroviral therapy;
PMTCT: prevention of mother-to-child transmission; IQR: Interquartile range.